Understanding the ins and outs of a rare disease like atypical hemolytic uremic syndrome (aHUS) is a difficult task for ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Recognising that challenge, AstraZeneca's rare disease unit Alexion has launched an interactive storybook that can help children with rare kidney disease atypical haemolytic uraemic syndrome (aHUS ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

A drug for Wilson disease developed by AstraZeneca's Alexion rare disease unit has cleared a phase 3 trial, setting up regulatory filings in the coming months. The FoCus study of ALXN1840 showed ...

Alexion, AstraZeneca Rare Diseasehas launcheda new electronic storybook (e-book) to support children living with rare kidney disease, atypical Haemolytic Uraemic Syndrome (aHUS). The interactive ...

The US Food and Drug Administration (FDA) has approved Alexion, AstraZeneca Rare Disease’s Ultomiris (ravulizumab-cwvz) to treat adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+ ...

From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology ...

2025--(BUSINESS WIRE)--Alexion, AstraZeneca Rare Disease has launched a new electronic storybook (e-book) to support children living with rare kidney disease, atypical Haemolytic Uraemic Syndrome ...